Embecta (NASDAQ:EMBC) Rating Lowered to Hold at Wall Street Zen

Embecta (NASDAQ:EMBC) was downgraded by equities researchers at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research note issued on Saturday.

Several other equities analysts also recently commented on the company. BTIG Research downgraded Embecta from a “buy” rating to a “neutral” rating in a report on Tuesday, May 5th. Weiss Ratings downgraded shares of Embecta from a “hold (c-)” rating to a “sell (d+)” rating in a report on Wednesday. Finally, Mizuho dropped their target price on shares of Embecta from $12.00 to $5.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Embecta presently has an average rating of “Reduce” and an average target price of $15.00.

Embecta Price Performance

NASDAQ EMBC opened at $3.64 on Friday. Embecta has a fifty-two week low of $3.45 and a fifty-two week high of $15.55. The stock’s 50-day moving average is $8.85 and its two-hundred day moving average is $11.06. The firm has a market cap of $215.96 million, a P/E ratio of 1.92 and a beta of 1.09.

Embecta (NASDAQ:EMBC) last released its quarterly earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.42 by ($0.15). Embecta had a negative return on equity of 23.96% and a net margin of 10.73%.The company had revenue of $221.80 million for the quarter, compared to the consensus estimate of $235.67 million. During the same quarter last year, the company posted $0.70 EPS. The business’s revenue was down 14.4% compared to the same quarter last year. Embecta has set its FY 2026 guidance at 1.550-1.75 EPS. On average, equities analysts expect that Embecta will post 1.58 EPS for the current year.

Hedge Funds Weigh In On Embecta

Several large investors have recently added to or reduced their stakes in EMBC. Larson Financial Group LLC grew its holdings in shares of Embecta by 368.6% during the 3rd quarter. Larson Financial Group LLC now owns 2,001 shares of the company’s stock worth $28,000 after purchasing an additional 1,574 shares in the last quarter. Tower Research Capital LLC TRC raised its stake in shares of Embecta by 542.6% in the second quarter. Tower Research Capital LLC TRC now owns 7,371 shares of the company’s stock valued at $71,000 after purchasing an additional 6,224 shares in the last quarter. Wexford Capital LP bought a new position in Embecta in the third quarter worth $94,000. Humankind Investments LLC bought a new position in Embecta in the second quarter worth $111,000. Finally, iSAM Funds UK Ltd acquired a new stake in Embecta during the third quarter worth $115,000. Institutional investors and hedge funds own 93.83% of the company’s stock.

Embecta Company Profile

Embecta Corp (NASDAQ: EMBC) is a pure-play diabetes care company that was spun off from Becton, Dickinson and Company on July 1, 2021. Headquartered in Franklin Lakes, New Jersey, Embecta focuses exclusively on the development, manufacturing and commercialization of products that enable insulin delivery and blood glucose monitoring for people with diabetes.

The company’s product portfolio includes insulin infusion sets, durable and patch pumps, pen needles, infusion tubing, blood glucose test strips, lancets and lancing devices.